Solid Biosciences Inc. (SLDB)
NASDAQ: SLDB · Real-Time Price · USD
4.160
+0.150 (3.74%)
At close: Dec 20, 2024, 4:00 PM
4.200
+0.040 (0.96%)
After-hours: Dec 20, 2024, 7:47 PM EST
Solid Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
88
Market Cap
166.21M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Fennec Pharmaceuticals | 49.35M |
2seventy bio | 45.62M |
Innate Pharma | 36.20M |
scPharmaceuticals | 30.28M |
Elutia | 24.78M |
Caribou Biosciences | 11.48M |
TScan Therapeutics | 9.36M |
Lyell Immunopharma | 63.00K |
SLDB News
- 8 days ago - Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst - Benzinga
- 25 days ago - Solid Biosciences to Participate at Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Solid Biosciences to Present at the Jefferies London Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 2 months ago - Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference - GlobeNewsWire
- 4 months ago - Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 6 months ago - Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire